Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-r...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2021-05, Vol.15 (3), p.410
Main Authors: Young-hwan Ahn, Heirim Lee, Do Young Kim, Hye Won Lee, Su Jong Yu, Young Youn Cho, Jeong Won Jang, Byoung Kuk Jang, Chang Wook Kim, Hee Yeon Kim, Hana Park, Hyo Jung Cho, Bumhee Park, Soon Sun Kim, Jae Youn Cheong
Format: Article
Language:Korean
Subjects:
Antiviral agents
Carcinoma
chronic
Hepatitis C
hepatocellular
Re-currence
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page 410
container_title Gut and liver
container_volume 15
creator Young-hwan Ahn
Heirim Lee
Do Young Kim
Hye Won Lee
Su Jong Yu
Young Youn Cho
Jeong Won Jang
Byoung Kuk Jang
Chang Wook Kim
Hee Yeon Kim
Hana Park
Hyo Jung Cho
Bumhee Park
Soon Sun Kim
Jae Youn Cheong
description Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (
format article
fullrecord <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_3887664</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>3887664</kiss_id><sourcerecordid>3887664</sourcerecordid><originalsourceid>FETCH-kiss_primary_38876643</originalsourceid><addsrcrecordid>eNp9jbtuwkAQAK8gUsjjC2j2ByyBDbYpkRNEOoTo0eqyxgvHnbW7JOIb8tMgkZpmpphiBm44mVdllud18exeVA_jcTnJq9nQ_X3Fb-rphmiwYT3CEr0lUWiTwIp6tOQphHNAgQbFc0wnhA35swhFT4CtkcAHC3nLFt447mERjX9YMMC2I8H-Ahxhjca3i8IvWwdNJymyvy_YWKF5c08tBqX3f7-60fJz26yyI6vueuETymVX1HVVltPicb0CShdOtw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C</title><source>PubMed Central</source><creator>Young-hwan Ahn ; Heirim Lee ; Do Young Kim ; Hye Won Lee ; Su Jong Yu ; Young Youn Cho ; Jeong Won Jang ; Byoung Kuk Jang ; Chang Wook Kim ; Hee Yeon Kim ; Hana Park ; Hyo Jung Cho ; Bumhee Park ; Soon Sun Kim ; Jae Youn Cheong</creator><creatorcontrib>Young-hwan Ahn ; Heirim Lee ; Do Young Kim ; Hye Won Lee ; Su Jong Yu ; Young Youn Cho ; Jeong Won Jang ; Byoung Kuk Jang ; Chang Wook Kim ; Hee Yeon Kim ; Hana Park ; Hyo Jung Cho ; Bumhee Park ; Soon Sun Kim ; Jae Youn Cheong</creatorcontrib><description>Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (&lt;12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (&lt;12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p&lt;0.001; HR 3.34, p&lt;0.001; and HR 1.74, p=0.006; respectively). Conclusions: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (&lt;12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15:410-419)</description><identifier>ISSN: 1976-2283</identifier><language>kor</language><publisher>대한간학회</publisher><subject>Antiviral agents ; Carcinoma ; chronic ; Hepatitis C ; hepatocellular ; Re-currence ; Risk factors</subject><ispartof>Gut and liver, 2021-05, Vol.15 (3), p.410</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Young-hwan Ahn</creatorcontrib><creatorcontrib>Heirim Lee</creatorcontrib><creatorcontrib>Do Young Kim</creatorcontrib><creatorcontrib>Hye Won Lee</creatorcontrib><creatorcontrib>Su Jong Yu</creatorcontrib><creatorcontrib>Young Youn Cho</creatorcontrib><creatorcontrib>Jeong Won Jang</creatorcontrib><creatorcontrib>Byoung Kuk Jang</creatorcontrib><creatorcontrib>Chang Wook Kim</creatorcontrib><creatorcontrib>Hee Yeon Kim</creatorcontrib><creatorcontrib>Hana Park</creatorcontrib><creatorcontrib>Hyo Jung Cho</creatorcontrib><creatorcontrib>Bumhee Park</creatorcontrib><creatorcontrib>Soon Sun Kim</creatorcontrib><creatorcontrib>Jae Youn Cheong</creatorcontrib><title>Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C</title><title>Gut and liver</title><addtitle>Gut and Liver</addtitle><description>Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (&lt;12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (&lt;12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p&lt;0.001; HR 3.34, p&lt;0.001; and HR 1.74, p=0.006; respectively). Conclusions: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (&lt;12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15:410-419)</description><subject>Antiviral agents</subject><subject>Carcinoma</subject><subject>chronic</subject><subject>Hepatitis C</subject><subject>hepatocellular</subject><subject>Re-currence</subject><subject>Risk factors</subject><issn>1976-2283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9jbtuwkAQAK8gUsjjC2j2ByyBDbYpkRNEOoTo0eqyxgvHnbW7JOIb8tMgkZpmpphiBm44mVdllud18exeVA_jcTnJq9nQ_X3Fb-rphmiwYT3CEr0lUWiTwIp6tOQphHNAgQbFc0wnhA35swhFT4CtkcAHC3nLFt447mERjX9YMMC2I8H-Ahxhjca3i8IvWwdNJymyvy_YWKF5c08tBqX3f7-60fJz26yyI6vueuETymVX1HVVltPicb0CShdOtw</recordid><startdate>20210530</startdate><enddate>20210530</enddate><creator>Young-hwan Ahn</creator><creator>Heirim Lee</creator><creator>Do Young Kim</creator><creator>Hye Won Lee</creator><creator>Su Jong Yu</creator><creator>Young Youn Cho</creator><creator>Jeong Won Jang</creator><creator>Byoung Kuk Jang</creator><creator>Chang Wook Kim</creator><creator>Hee Yeon Kim</creator><creator>Hana Park</creator><creator>Hyo Jung Cho</creator><creator>Bumhee Park</creator><creator>Soon Sun Kim</creator><creator>Jae Youn Cheong</creator><general>대한간학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20210530</creationdate><title>Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C</title><author>Young-hwan Ahn ; Heirim Lee ; Do Young Kim ; Hye Won Lee ; Su Jong Yu ; Young Youn Cho ; Jeong Won Jang ; Byoung Kuk Jang ; Chang Wook Kim ; Hee Yeon Kim ; Hana Park ; Hyo Jung Cho ; Bumhee Park ; Soon Sun Kim ; Jae Youn Cheong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_38876643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2021</creationdate><topic>Antiviral agents</topic><topic>Carcinoma</topic><topic>chronic</topic><topic>Hepatitis C</topic><topic>hepatocellular</topic><topic>Re-currence</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Young-hwan Ahn</creatorcontrib><creatorcontrib>Heirim Lee</creatorcontrib><creatorcontrib>Do Young Kim</creatorcontrib><creatorcontrib>Hye Won Lee</creatorcontrib><creatorcontrib>Su Jong Yu</creatorcontrib><creatorcontrib>Young Youn Cho</creatorcontrib><creatorcontrib>Jeong Won Jang</creatorcontrib><creatorcontrib>Byoung Kuk Jang</creatorcontrib><creatorcontrib>Chang Wook Kim</creatorcontrib><creatorcontrib>Hee Yeon Kim</creatorcontrib><creatorcontrib>Hana Park</creatorcontrib><creatorcontrib>Hyo Jung Cho</creatorcontrib><creatorcontrib>Bumhee Park</creatorcontrib><creatorcontrib>Soon Sun Kim</creatorcontrib><creatorcontrib>Jae Youn Cheong</creatorcontrib><collection>KISS</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Gut and liver</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Young-hwan Ahn</au><au>Heirim Lee</au><au>Do Young Kim</au><au>Hye Won Lee</au><au>Su Jong Yu</au><au>Young Youn Cho</au><au>Jeong Won Jang</au><au>Byoung Kuk Jang</au><au>Chang Wook Kim</au><au>Hee Yeon Kim</au><au>Hana Park</au><au>Hyo Jung Cho</au><au>Bumhee Park</au><au>Soon Sun Kim</au><au>Jae Youn Cheong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C</atitle><jtitle>Gut and liver</jtitle><addtitle>Gut and Liver</addtitle><date>2021-05-30</date><risdate>2021</risdate><volume>15</volume><issue>3</issue><spage>410</spage><pages>410-</pages><issn>1976-2283</issn><abstract>Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (&lt;12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (&lt;12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p&lt;0.001; HR 3.34, p&lt;0.001; and HR 1.74, p=0.006; respectively). Conclusions: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (&lt;12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15:410-419)</abstract><pub>대한간학회</pub><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1976-2283
ispartof Gut and liver, 2021-05, Vol.15 (3), p.410
issn 1976-2283
language kor
recordid cdi_kiss_primary_3887664
source PubMed Central
subjects Antiviral agents
Carcinoma
chronic
Hepatitis C
hepatocellular
Re-currence
Risk factors
title Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T06%3A01%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Independent%20Risk%20Factors%20for%20Hepatocellular%20Carcinoma%20Recurrence%20after%20Direct-Acting%20Antiviral%20Therapy%20in%20Patients%20with%20Chronic%20Hepatitis%20C&rft.jtitle=Gut%20and%20liver&rft.au=Young-hwan%20Ahn&rft.date=2021-05-30&rft.volume=15&rft.issue=3&rft.spage=410&rft.pages=410-&rft.issn=1976-2283&rft_id=info:doi/&rft_dat=%3Ckiss%3E3887664%3C/kiss%3E%3Cgrp_id%3Ecdi_FETCH-kiss_primary_38876643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=3887664&rfr_iscdi=true